Patent Requirements
Utility Requirement
What makes an invention patentably "useful" — and where the standard gets strict.
Quick Answer
35 U.S.C. § 101 requires that a patented invention be "useful." The USPTO's standard — specific, substantial, and credible utility — sets a low bar for most inventions but is genuinely demanding for early-stage biotech/pharma compounds where human therapeutic utility must be credibly established from pre-clinical data.
The Standard
Specific, Substantial & Credible Utility
The utility requirement traces to the constitutional requirement of "useful Arts" (Art. I, § 8, cl. 8) and is codified in 35 U.S.C. § 101. For most inventions — mechanical devices, consumer products, process improvements — utility is obvious and never questioned. The requirement becomes contentious in biotechnology and chemistry, where a compound may be structurally novel but functionally uncharacterized.
Particular to the claimed invention
The utility must be specific to the subject matter claimed — not generic to an entire class of molecules or methods. 'Useful as a research tool' or 'useful for further study' does not satisfy specific utility. Example: 'inhibits kinase X, potentially useful for treating cancer' is insufficient; 'inhibits EGFR kinase in vitro, demonstrating potential for treating NSCLC by the mechanism of…' is stronger.
Example failure: EST claiming 'useful as a probe' without identified gene function fails.
Real-world, non-speculative value
The utility must provide a real benefit to society — not just theoretical or speculative use. Perpetual motion machines, purely abstract mathematical results, and speculative future applications fail. A chemical compound with confirmed in vitro cytotoxicity against a cancer cell line has substantial utility; a compound 'believed to be potentially useful in medicine' without data does not.
Example failure: A 'cure for all disease' claim without supportive data fails.
Believable to a POSITA
Would a person of ordinary skill in the art believe the asserted utility based on the specification and common knowledge? This is an objective standard. For well-established technology, nearly all utilities are credible. In emerging fields (gene therapy, nanotechnology, novel drug modalities), the credibility threshold is higher — the spec may need animal data, mechanism of action, or structural analogy to known active compounds.
Example failure: Novel receptor agonist 'useful for diabetes' with no mechanism or data fails.
Biotech & Pharma
Utility in Biotechnology and Pharmaceuticals
Utility is most litigated in biotech. Key precedents:
In re Brana (Fed. Cir. 1995)
In vitro cytotoxicity data can establish credible utility for anti-tumor compounds without in vivo human data, if a POSITA would believe the correlation. The burden shifts to the USPTO once the applicant provides a reasonable correlation.
In re Fisher (Fed. Cir. 2005)
Expressed sequence tags (ESTs) with only generic research utility fail the specific and substantial utility tests. Utility must identify a function specifically tied to the EST's gene product, not just general use as a probe or research tool.
Brenner v. Manson (S.Ct. 1966)
A novel chemical compound with no known use has no patentable utility — 'a patent is not a hunting license.' The steroid compound was well-synthesized but its only use was further research; that was insufficient for § 101 utility.
Rasmusson v. SmithKline Beecham (Fed. Cir. 2004)
Negative clinical trial data can retroactively undermine credibility of asserted utility if the POSITA would not have believed the utility at filing, even if the examiner did not have the clinical data at the time.
Operability
Inoperable Inventions and § 101
Inventions that simply do not work — perpetual motion machines, methods that violate the laws of physics, devices that cannot achieve their stated purpose — fail the utility requirement because they lack any real-world benefit. Examiners may reject such claims under § 101 (no utility) and also under § 112 (non-enabling) since a POSITA cannot make and use what doesn't function.
Operability is presumed for most inventions unless the examiner has specific reason to doubt it (e.g., the claimed result requires violating known physical laws, or the claimed biological effect is unknown for the compound class). The USPTO may request experimental data to support operability when the claimed utility is facially incredible.
FAQ
What is the utility requirement for a patent?
35 U.S.C. § 101 requires that an invention be 'useful.' The USPTO's 2001 Utility Examination Guidelines established a three-part standard: the utility must be (1) specific — particular to the claimed invention, not a general class; (2) substantial — real-world value beyond theoretical or speculative benefit; (3) credible — believable to a person of ordinary skill in the art based on the totality of the disclosure and common knowledge.
Can a DNA sequence or gene fragment lack utility?
Yes — expressed sequence tags (ESTs) and partial gene fragments frequently failed utility review pre-AIA because their specific function was unknown. An applicant who discloses only that a DNA sequence 'is useful for research' without identifying a specific function fails the specific utility prong. The utility must be tied to a particular function: e.g., the gene encodes Protein X which inhibits Pathway Y implicated in Disease Z.
Is therapeutic utility established by in vitro data alone?
It depends on the technology. For pharmaceutical/biotech claims, the Federal Circuit held in In re Brana (1995) that in vivo animal testing data is not required if a POSITA would believe the in vitro or in vivo animal data credibly predicts human therapeutic utility. However, if the claimed compound class is unpredictable or correlation to human activity is weak, more evidence is required. The credibility threshold rises with therapeutic seriousness.
Does a product that works but isn't commercially viable have utility?
Yes. Commercial utility is not required — legal utility under § 101 is satisfied by any real-world use, however modest. A safe but highly inefficient process still has utility. Courts have said an invention need only have a single beneficial use. The low bar for utility under § 101 is distinct from the commercial and market viability questions that affect whether filing is economically wise.
What happens if utility is rejected during prosecution?
The examiner must provide a rejection specifically identifying why the claimed utility is specific/substantial/credible deficiency — a bare 'lacks utility' rejection is procedurally deficient. The applicant can rebut by: (1) pointing to language in the specification establishing specific utility; (2) submitting a § 132 declaration from a POSITA confirming credibility; (3) amending the claims and/or specification to add explicit utility statements; (4) citing prior art establishing the known utility of structurally similar compounds or methods.
Related Guides